ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 451 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of Disease Activity By The Routine Assessment Of Patient Index Data 3 In Patients With Rheumatoid Arthritis Receiving Tocilizumab

    Yu F. Asanuma1, Takashi Maruyama2, Maiko Yanagisawa2, Kazuhiro Yokota3, Yoshihiro Yoshida2, Hiroshi Kajiyama1, Kojiro Sato1, Yuji Akiyama1 and Toshihide Mimura4, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 2Saitama Medical University, Saitama, Japan, 3Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 4Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Interleukin-6 (IL-6) has been demonstrated to play a pathological role in rheumatoid arthritis (RA). IL-6 strongly induces production of C-reactive protein (CRP) and fibrinogen…
  • Abstract Number: 2683 • 2013 ACR/ARHP Annual Meeting

    Application Of a Multi-Biomarker Disease Activity (Vectra® DA) Score For Assessing Rheumatoid Arthritis Patients With Fibromyalgia Or Low C-Reactive Protein

    Yvonne C. Lee1, James Hackett2, Claire Alexander3, Michelle A. Frits1, Christine K. Iannaccone1, Nancy A. Shadick4, Michael E. Weinblatt5, Oscar Segurado6 and Eric H. Sasso6, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Hackett & Associates, Inc., San Diego, CA, 3Clinical Operations, Crescendo Bioscience Inc., South San Francisco, CA, 4Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, 5Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, 6Crescendo Bioscience Inc., South San Francisco, CA

    Background/Purpose: Clinical assessment of rheumatoid arthritis (RA) may be challenging if patients have fibromyalgia (FM) or if C-reactive protein (CRP) is low (£1 mg/dL). A…
  • Abstract Number: 2279 • 2013 ACR/ARHP Annual Meeting

    Assessment Of Global Disease Activity In Rheumatoid Arthritis By Patients and Physicians: Cultural Differences Among Countries In The Meteor Database

    E. Gvozdenovic1, R. Wolterbeek2, C.F. Allaart1, Claiton Brenol3, Arvind Chopra4, Maxime Dougados5, Paul Emery6, D. van der Heijde7, T.W.J. Huizinga1, Jonathan Kay8, Emilio Martín Mola9, Robert J. Moots10, José A. P. Da Silva11, Josef S. Smolen12, Douglas J. Veale13 and R. Landewe14, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Biostatistics, Leiden University Medical Center, Leiden, Netherlands, 3Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, 4Rheumatology, Center for Rheumatic Diseases, Pune, India, 5Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 6Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 8UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, 9Rheumatology. La Paz Hospital. IdiPaz, Madrid, Spain, 10Clinical Sciences Centre, University of Liverpool, Liverpool, United Kingdom, 11Serviço de Reumatologia, Centro Hospitalar e Universitário de Coimbra – Hospitais da Universidade de Coimbra, E.P.E., Coimbra, Portugal, 12Medical University of Vienna, Vienna, Austria, 13Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 14Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: Dissonant perceptions of disease activity between rheumatoid arthritis (RA) patients and their rheumatologists may influence treatment decisions. The discordance between patient's and physician's global…
  • Abstract Number: 1863 • 2013 ACR/ARHP Annual Meeting

    SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity

    Elena Gkrouzman1, Mikhail Olferiev1, Margaret Robotham1, Mari Lliguicota1, Wei-Ti Huang2, Elzbieta E. Jacek1, Kyriakos A. Kirou1 and Mary K. Crow3, 1Hospital for Special Surgery, New York, NY, 2Biostatistics, Hospital for Special Surgery, New York, NY, 3Department of Medicine, Hospital for Special Surgery, New York, NY

    Background/Purpose: Type I interferon (IFN-I) has been implicated in SLE pathogenesis, and cross-sectional studies have shown that IFN-I pathway activation is associated with multiple disease…
  • Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting

    Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis

    Edward Keystone1, MC Genovese2, Peter Taylor3, Baojin Zhu4, Scott D. Beattie4, Stephanie de Bono4, Terence Rooney4, Douglas E. Schlichting4 and William Macias4, 1University of Toronto, Toronto, ON, Canada, 2Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, 3NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 4Eli Lilly and Company, Indianapolis, IN

    Background/Purpose:   Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…
  • Abstract Number: 1026 • 2013 ACR/ARHP Annual Meeting

    Impact Of Basing Rheumatoid Arthritis Disease Activity Measurement and Treatment Recommendations On Patient Instead Of Physician Joint Assessments

    Yomei Shaw1, Daisy Bang2, Heather Eng3, Stephen R. Wisniewski4, Mark S. Roberts1 and Marc C. Levesque5, 1Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 2Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, 3Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 4Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Current guidelines recommend treatment for rheumatoid arthritis (RA) be informed by a measure of disease activity such as the Disease Activity Score-28 (DAS28-CRP), which…
  • Abstract Number: 422 • 2013 ACR/ARHP Annual Meeting

    Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry

    Helga Midtbø1, Eva Gerdts1,2, Inge C. Olsen3, Tore K. Kvien4, Einar Davidsen1 and Anne Grete Semb3, 1Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, 2Department of Cinical Science, University of Bergen, Bergen, Norway, 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose :Disease activity is related to risk of cardiovascular (CV) disease in rheumatoid arthritis (RA) patients1,2. Left ventricular (LV) geometry strongly predicts CV mortality and…
  • Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting

    Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice

    Jos Hendrikx1, Jaap Fransen2, Alessandro Toniolo3 and Piet L.C.M. van Riel4, 1Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Pfizer Pharmaceuticals, Rome, Italy, 4Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist,  though an evidence base for their use in monitoring…
  • Abstract Number: 2280 • 2013 ACR/ARHP Annual Meeting

    Stiffness From The Perspective Of People Living With Rheumatoid Arthritis

    Ana-Maria Orbai1, Katherine Clegg-Smith2, Susan J. Bartlett3, Elaine De Leon4, Michelle Jones5 and Clifton O. Bingham III1, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Health Behavior and Society, Johns Hopkins University School of Public Health, Baltimore, MD, 3Clinical Epidemiology, McGill University, Montreal, QC, Canada, 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 5Johns Hopkins University, Baltimore, MD

    Background/Purpose: Stiffness was included in the 1961 and 1987 Rheumatoid Arthritis (RA) classification criteria and continues to be commonly queried in clinical care.  Its relative…
  • Abstract Number: 1788 • 2013 ACR/ARHP Annual Meeting

    The Multi-Biomarker Disease Activity Test (Vectra® DA) Estimates Risk Of Radiographic Progression For Patients With Rheumatoid Arthritis From The Leiden Early Arthritis Clinic

    Wanying Li1, DJ Haney1, Guy Cavet1, Thomas W. Huizinga2, Eric H. Sasso1 and A. H. M. van der Helm-van Mil3, 1Crescendo Bioscience Inc., South San Francisco, CA, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The multi-biomarker disease activity (MBDA) blood test assesses disease activity in patients with rheumatoid arthritis (RA) using a validated algorithm to provide a score…
  • Abstract Number: 1357 • 2013 ACR/ARHP Annual Meeting

    Coping Style Is An Independent Predictor For Disease Activity At Three Months In Early Arthritis Patients Initiating Therapy With Disease Modifying Anti-Rheumatic Drugs

    T. Martijn Kuijper1, Hong Xiong2, A.E.a.M. Weel3, A.H. Gerards4, Jendé van Zeben5, P.H.P. de Jong6, Ilja Tchetverikov7, P.B.J. de Sonnaville8, M.V. Krugten9, B.A. Grillet10, Jolanda J. Luime2 and Johanna M.W. Hazes11, 1Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 3Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 4Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 5Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 6Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 7Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, 8Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, 9Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, 10Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands, 11Rheumatology, Erasmus MC, Rotterdam, Netherlands

    Background/Purpose: To explore the effect of psychosocial factors on the Disease Activity Score (DAS) and its components in early arthritis patients three months after initiating…
  • Abstract Number: 1029 • 2013 ACR/ARHP Annual Meeting

    Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea

    Yoon-Kyoung Sung1,2, Kazuki Yoshida2,3, Femke H.M. Prince2,4, Michelle A. Frits2, Jung-Yoon Choe5, Won Tae Chung6, Jisoo Lee7, Eun-Mi Koh8, Dae-Hyun Yoo9, Simon M. Helfgott2, Nancy A. Shadick10, Michael E. Weinblatt11, Sang-Cheol Bae1 and Daniel H. Solomon2, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 3Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, 4Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, 5Catholic University of Daegu School of Medicine, Daegu, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, 7Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, 8Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 9Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 10Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, 11Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Quality of life (QOL) is a well-established outcome for rheumatoid arthritis (RA) trials. To perform trials with QOL as an outcome involving many countries,…
  • Abstract Number: 380 • 2013 ACR/ARHP Annual Meeting

    Active Rheumatoid Arthritis Is An Independent Risk Factor Of Chronic Kidney Disease

    Ryosuke Hanaoka1,2, Kazuhiro Kurasawa3, Ayae Tanaka4 and Harutsugu Okada5, 1Department of Rheumatology, Kamitsuga General Hospital, Kanuma, Japan, 2Department of Rheumatology, Kamitsuga General Hospital, Kanuma, Tochigi, Japan, 3Clinical Immunology, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, 4Clinical Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan, 5Clinical Immunology, Dokkyo Medical University, Mibu-machi, Tochigi-ken, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects not only joints but also many organs. RA causes vascular damages to contribute to…
  • Abstract Number: 2569 • 2013 ACR/ARHP Annual Meeting

    Serum S100A4 Levels Correlate With Skin Fibrosis and Lung Involvement In Systemic Sclerosis

    Michal Tomcik1, Lucie Andres Cerezo1, Simona Skacelova2, Martin Komarc3, Radim Becvar1, Mariam Grigorian4, Joerg HW Distler5 and Ladislav Senolt1, 1Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 3Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic, 4Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark, 5Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Our previous study demonstrated that S100A4 is overexpressed in scleroderma (SSc) skin, fibroblasts and preclinical models of SSc in a TGF-β dependent manner. Furthermore,…
  • Abstract Number: 2251 • 2013 ACR/ARHP Annual Meeting

    Variability in the Classification of Remission Among Disease Activity Indices and Their Correlation: An Analysis From a  Prospective, Observational Registry

    William G. Bensen1, Algis V Jovaisas2, J. Carter Thorne3, Philip Baer4, Majed M. Khraishi5, Sanjay Dixit6, Denis Choquette7, Michael Starr8, Isabelle Fortin9, Dalton E. Sholter10, Emmanouil Rampakakis11,12, John S. Sampalis11,12, Francois Nantel13, Allen J. Lehman14, May Shawi15 and Susan M. Otawa14, 1Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 2Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Southlake Regional Health Centre, Newmarket, ON, Canada, 4Private Practice, Scarborough, ON, Canada, 5Nexus Clinical Research, St John's, NF, Canada, 6McMaster University, Hamilton, ON, Canada, 7Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 8Montreal General Hospital, Montreal, QC, Canada, 9Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, 10Rheumatology Associates, Edmonton, AB, Canada, 11JSS Medical Research, Montreal, QC, Canada, 12Jewish General Hospital, McGill University, Montreal, QC, Canada, 13Janssen Inc., Toronto, ON, Canada, 14Medical Affairs, Janssen Inc., Toronto, ON, Canada, 15Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: In recent years, disease remission in rheumatoid arthritis (RA) has been assessed using various disease activity indices such as the DAS28-CRP, SDAI, CDAI, ACR/EULAR-recommended…
  • « Previous Page
  • 1
  • …
  • 96
  • 97
  • 98
  • 99
  • 100
  • …
  • 102
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology